Singapore, Central Region, Singapore The company was established in Asia in Singapore. The main office of represented VC is situated in the Singapore.
Among the most popular portfolio startups of the fund, we may highlight Tessa Therapeutics, ONE Championship. We can highlight the next thriving fund investment areas, such as Media and Entertainment, Biotechnology. Besides, a startup needs to be aged 16-20 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - Singapore.
The overall number of key employees were 5.
The common things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. Opposing the other organizations, this Heliconia Capital Management works on 4 percentage points less the average amount of lead investments. The typical startup value when the investment from Heliconia Capital Management is 100-500 millions dollars. The important activity for fund was in 2017. The fund is generally included in 2-6 deals every year.
The typical case for the fund is to invest in rounds with 2-3 participants. The meaningful sponsors for the fund in investment in the same round are Temasek Holdings, Singtel Innov8, Sequoia Capital India. In the next rounds fund is usually obtained by Temasek Holdings, Sequoia Capital, Greenoaks Capital.
Funds with similar focus
Discover 4 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Tessa Therapeutics | $126M | 09 Jun 2022 | Singapore, Central, Singapore | ||
ADDX | $58M | 24 May 2022 | Singapore, Central Region, Singapore | ||
Glife Technologies | $2M | 20 May 2022 | Singapore, Central, Singapore | ||
Crown Digital | $3M | 20 Apr 2022 | Singapore, Central Region, Singapore | ||
Haulio | $7M | 22 Dec 2021 | Singapore, Central, Singapore | ||
Glife Technologies | $8M | 16 Nov 2021 | Singapore, Central, Singapore | ||
ADDX | $48M | 21 Jan 2021 | Singapore, Central, Singapore | ||
Lucence Health | $20M | 20 Nov 2019 | Palo Alto, California, United States | ||
Secretlab | $7M | 13 Aug 2019 | Singapore, Central, Singapore |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Tessa Therapeutics | $126M | 09 Jun 2022 | Singapore, Central, Singapore | ||
ADDX | $58M | 24 May 2022 | Singapore, Central Region, Singapore | ||
Glife Technologies | $2M | 20 May 2022 | Singapore, Central, Singapore | ||
Crown Digital | $3M | 20 Apr 2022 | Singapore, Central Region, Singapore | ||
Haulio | $7M | 22 Dec 2021 | Singapore, Central, Singapore | ||
Glife Technologies | $8M | 16 Nov 2021 | Singapore, Central, Singapore | ||
ADDX | $48M | 21 Jan 2021 | Singapore, Central, Singapore | ||
Lucence Health | $20M | 20 Nov 2019 | Palo Alto, California, United States | ||
Secretlab | $7M | 13 Aug 2019 | Singapore, Central, Singapore |
